Title

Targeting epigenetics for the treatment of prostate cancer: Recent progress and future directions

Document Type

Journal Article

Publication Date

1-1-2013

Journal

Seminars in Oncology

Volume

40

Issue

3

DOI

10.1053/j.seminoncol.2013.04.010

Abstract

Epigenetic aberrations contribute to prostate cancer carcinogenesis and disease progression. Efforts have been made to target DNA methyltransferase and histone deacetylases (HDACs) in prostate cancer and other solid tumors but have not had the success that was seen in the hematologic malignancies. Oral, less toxic, and more specific agents are being developed in solid tumors including prostate cancer. Combinations of epigenetic agents alone or with a targeted agent such as androgen receptor signaling inhibitors are promising approaches and will be discussed further. © 2013 Elsevier Inc.

Share

COinS